The report said Pfizer will license Selzentry, its oral HIV medicine, to the International Partnership for Microbicides, which will try to turn it into a vaginal gel, ring, or film that prevents transmission of the virus.
NEW YORK (Reuters) - Pfizer Inc is seeking to reformulate its HIV drug to prevent the transmission of the virus through a partnership with a nonprofit group, The Wall Street Journal reported on Wednesday.
The report said Pfizer will license Selzentry, its oral HIV medicine, to the International Partnership for Microbicides, which will try to turn it into a vaginal gel, ring, or film that prevents transmission of the virus.
Pfizer officials were not immediately available for comment.
Selzentry was the first drug designed to keep the HIV virus that causes AIDS from entering healthy immune cells. Older AIDS drugs attack the virus itself.
!ADVERTISEMENT!(Reporting by Ritsuko Ando)
